{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:00:41Z","timestamp":1783443641115,"version":"3.54.6"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12185-024-03869-y","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T15:01:49Z","timestamp":1730991709000},"page":"272-275","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of asciminib in a patient with chronic myeloid leukemia on hemodialysis"],"prefix":"10.1007","volume":"121","author":[{"given":"Ryosuke","family":"Naka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1018-9508","authenticated-orcid":false,"given":"Yoshimitsu","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatomo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadakazu","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"3869_CR1","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381:2315\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1902328.","journal-title":"N Engl J Med"},{"key":"3869_CR2","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384. https:\/\/doi.org\/10.1038\/s41375-020-0776-2.","journal-title":"Leukemia"},{"key":"3869_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.dmpk.2015.09.002","volume":"31","author":"M Miura","year":"2016","unstructured":"Miura M, Takahashi N. Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC-UV or LC-MS\/MS methods. Drug Metab Pharmacokinet. 2016;31:12\u201320. https:\/\/doi.org\/10.1016\/j.dmpk.2015.09.002.","journal-title":"Drug Metab Pharmacokinet"},{"key":"3869_CR4","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1002\/cncr.29587","volume":"121","author":"M Yilmaz","year":"2015","unstructured":"Yilmaz M, Lahoti A, O\u2019Brien S, et al. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015;121:3894\u2013904. https:\/\/doi.org\/10.1002\/cncr.29587.","journal-title":"Cancer"},{"issue":"4","key":"3869_CR5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s00280-005-1031-2","volume":"56","author":"P Pappas","year":"2005","unstructured":"Pappas P, Karavasilis V, Briasoulis E, Pavlidis N, Marselos M. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. Cancer Chemother Pharmacol. 2005;56(4):358\u201360. https:\/\/doi.org\/10.1007\/s00280-005-1031-2.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3869_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12185-020-02846-5","volume":"112","author":"J Mori","year":"2020","unstructured":"Mori J, Oshima K, Tanimoto T, et al. Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease. Int J Hematol. 2020;112(1):115\u20137. https:\/\/doi.org\/10.1007\/s12185-020-02846-5.","journal-title":"Int J Hematol"},{"key":"3869_CR7","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.2169\/internalmedicine.4871-20","volume":"59","author":"Y Taniguchi","year":"2020","unstructured":"Taniguchi Y, Takahashi N, Miura M, et al. The impact of hemodialysis and liver cirrhosis on the plasma concentrations of tyrosine kinase inhibitors in a patient with chronic myeloid leukemia. Intern Med. 2020;59:2745\u20139. https:\/\/doi.org\/10.2169\/internalmedicine.4871-20.","journal-title":"Intern Med"},{"key":"3869_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/ajh.23125","volume":"87","author":"T Onaka","year":"2012","unstructured":"Onaka T, Takahashi N, Miura M, Yonezawa A, Imada K, Sawada K. Pharmacokinetics of nilotinib in imatinib-resistant\/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure. Am J Hematol. 2012;87:45. https:\/\/doi.org\/10.1002\/ajh.23125.","journal-title":"Am J Hematol"},{"key":"3869_CR9","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.2007.13.3819","volume":"26","author":"J Gibbons","year":"2008","unstructured":"Gibbons J, Egorin MJ, Ramanathan RK, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. JCO. 2008;26:570\u20136. https:\/\/doi.org\/10.1200\/JCO.2007.13.3819.","journal-title":"JCO"},{"key":"3869_CR10","doi-asserted-by":"publisher","first-page":"6247","DOI":"10.1007\/s00432-022-04562-5","volume":"149","author":"E Atallah","year":"2023","unstructured":"Atallah E, Mauro MJ, Hochhaus A, et al. Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors. J Cancer Res Clin Oncol. 2023;149:6247\u201362. https:\/\/doi.org\/10.1007\/s00432-022-04562-5.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"S1","key":"3869_CR11","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.5045\/br.2023.2023017","volume":"58","author":"EJ Choi","year":"2023","unstructured":"Choi EJ. Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase. Blood Res. 2023;58(S1):S29\u201336. https:\/\/doi.org\/10.5045\/br.2023.2023017.","journal-title":"Blood Res"},{"key":"3869_CR12","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/jcph.1926","volume":"61","author":"M Hoch","year":"2021","unstructured":"Hoch M, Sato M, Zack J, et al. Pharmacokinetics of asciminib in individuals with hepatic or renal impairment. J Clin Pharmacol. 2021;61:1454\u201365. https:\/\/doi.org\/10.1002\/jcph.1926.","journal-title":"J Clin Pharmacol"},{"key":"3869_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000535958","volume":"17","author":"A Alshurafa","year":"2024","unstructured":"Alshurafa A, Adil A, Yassin MA. Safety and efficacy of asciminib in chronic myeloid leukemia patient with chronic kidney diseases: a case report. Case Rep Oncol. 2024;17:96\u2013100. https:\/\/doi.org\/10.1159\/000535958.","journal-title":"Case Rep Oncol"},{"key":"3869_CR14","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.2169\/internalmedicine.2179-23","volume":"63","author":"Y Uchida","year":"2023","unstructured":"Uchida Y, Koyama D, Manabe K, et al. High efficacy and safety of asciminib in a chronic myeloid leukemia patient with chronic kidney disease following renal transplantation: a case report. Intern Med. 2023;63:2179\u20132123. https:\/\/doi.org\/10.2169\/internalmedicine.2179-23.","journal-title":"Intern Med"},{"key":"3869_CR15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400858","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus A, Wang J, Kim DW, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2400858.","journal-title":"N Engl J Med"},{"key":"3869_CR16","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s40262-022-01148-9","volume":"61","author":"YF Li","year":"2022","unstructured":"Li YF, Combes FP, Hoch M, et al. Population pharmacokinetics of asciminib in tyrosine kinase inhibitor-treated patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic and acute phases. Clin Pharmacokinet. 2022;61:1393\u2013403. https:\/\/doi.org\/10.1007\/s40262-022-01148-9.","journal-title":"Clin Pharmacokinet"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03869-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03869-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03869-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:35:16Z","timestamp":1738254916000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03869-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3869"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03869-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"assertion":[{"value":"30 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}